Clinical Trial

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further development of the vaccine.
Summary
The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.
Protocol Amendment History 5 changes
critical Trial terminated 2026-08-06
critical Trial terminated: The clinical study was terminated prior to the start of Phase 2 following a business decision to discontinue further de... 2026-08-06
critical Phase changed: Phase 1/2 -> Phase 1 2026-08-06
notable Primary completion moved earlier: 2026-06-30 -> 2025-12-31 2026-08-06
minor Completion moved earlier: 2026-06-30 -> 2025-12-31 2026-08-06
Trial Details
NCT Number NCT05701800
Lead Sponsor ModernaTX, Inc.
Conditions Herpes Zoster
Enrollment 659 participants
Start Date 2023-01-23
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-05